NCT01968265View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

May 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ISIS-GCCRRx

3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin

DRUG

Placebo

3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin

Trial Locations (14)

1501

Isis Investigative Site, Benoni

1818

Isis Investigative Site, Soweto

7130

Isis Investigative Site, Somerset West

9300

Isis Investigative Site, Bloemfontein

400349

Isis Investigative Site, Cluj-Napoca

Unknown

Isis Investigative Site, Red Deer

Isis Investigative Site, Penticton

Isis Investigative Site, Cornwall

Isis Investigative Site, Courtice

Isis Investigative Site, Greater Sudbury

H2R1V6

Isis Investigative Site, Montreal

010507

Isis Investigative Site, Bucharest

011794

Isis Investigative Site, Bucharest

022441

Isis Investigative site, Bucharest

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY